Gilead Sciences (GILD) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

GILD Gilead Sciences

Watchlist

63.380
-0.890-1.38%

Trading Jun 3 13:35 ET

78.96BMarket Cap176.06P/E (TTM)

Intraday

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

After Disappointing Bladder Cancer Data, Gilead Announces Encouraging Data From Gastric, Colorectal Cancer Studies
On Saturday, Gilead Sciences Inc (NASDAQ:GILD) and Arcus Biosciences Inc (NYSE:RCUS) released longer-term efficacy and safety results from Arm A1 of the Phase 2 EDGE-Gastric study.The updated data sho
Benzinga12:35 ET
Gilead Sciences Unit Says Tecartus Improves Overall Survival in Leukemia, Yescarta Well-Tolerated in Lymphoma
Gilead Sciences' (GILD) Kite unit said Monday that the phase 1/2 study assessing CAR T-cell therapy Tecartus in adults with relapsed or refractory B-cell acute lymphoblastic leukemia showed a median o
MT Newswires12:09 ET
Express News | Kite: After More Than Four Years of Follow-up in Pivotal Zuma-3 Study, Median Overall Survival (Os) Was 26 Months and Os Rate Was 40% at 48 Months
ReutersJun 3 10:05 ET
Express News | Kite: Tecartus Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
ReutersJun 3 10:04 ET
Express News | Kite's Tecartus Shows 40% Four-Year Overall Survival Rate In Pivotal ZUMA-3 Study For Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
BenzingaJun 3 10:01 ET
Kite's Tecartus Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
-- After More Than Four Years of Follow-up in the Pivotal ZUMA-3 Study, Median Overall Survival (OS) was 26 Months and the OS Rate was 40% at 48 Months -- -- Survival Benefit was Seen Regardless of Age, Prior
BusinesswireJun 3 10:00 ET

Comments

Pinkiii

May 30 06:20

$gild

$Gilead Sciences(GILD.US)$
ps: please do your own due diligence before any investing

Gilead Sciences Partners With White House for Early Cancer Detection Program "Biden Cancer Moonshot"

Meltyy

May 22 02:52

Biotech Stock Catalyst Watchlist 👀

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics(IOVA.US)$ Phase 2
$Supernus Pharmaceuticals(SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US)$ Phase 2a
$MorphoSys(MOR.US)$ Phase 2
$Nuvation Bio(NUVB.US)$ Phase 2
$ALX Oncology(ALXO.US)$ Phase 2
$BioXcel Therapeutics(BTAI.US)$ Phase 2
$Purple Biotech(PPBT.US)$ Phase 2
$Arcus Biosciences(RCUS.US)$ Phase 2
$Medicenna Therapeutics(MDNAF.US)$ Phase 2b
$Affimed NV(AFMD.US)$ Phase 2
$Barinthus Biotherapeutics(BRNS.US)$ Phase 2b...

Shaaaw

May 8 05:01

No megadeals in biotech so far this yr, but on track for record amount >$1 bil deals,
2 biggest deals this yr:
$Vertex Pharmaceuticals(VRTX.US)$ paid $4.9 bil for $Alpine Immune(ALPN.US)$
$Gilead Sciences(GILD.US)$ paid $4.3 bil for $CBAY
Bolt-on deals likely to continue to be the dominant story in 2024, which means we could also see more of this trend...
Last yr 84% of M&A deal dollars were for Biotechs w/ Phase 3 & Marketed assets,
In the first four months of 2024 56% of M&A deal dollar went towards P...

Pinkiii

Apr 28 08:26

$Gilead Sciences(GILD.US)$

Expand

Luzi Ann Santos

Apr 26 14:46

Gilead Sciences Sees Deep-Pocketed Investors Take Bullish Stance, Benzinga Reports

Deep-pocketed investors have taken a bullish approach towards $Gilead Sciences(GILD.US)$, Benzinga reported, cited nine extraordinary options activities linked to the stock. About 77% of the trades were leaning bullish and 22% bearish, according to the report.
Four of them were puts, totaling $495,628, and five were calls, amounting to $213,111, the report showed. The volume and open interest data on the contract...